Search

Now showing items 1-2 of 2

Comparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types

Aydoğdu, Selime; Toret, Ersin; Aksoy, Başak A.; Aydın, Muhammed Fatih; Cipe, Funda E.; Bozkurt, Ceyhun; Fışgın, Tunç (Taylor & Francis Ltd, 2021)

Allogeneic hematopoietic stem cell transplantation (HSCT) is the curative therapy for beta-thalassemias that induces severe life-threatening complications. The human leukocyte antigen (HLA) registries and umbilical cord ...

Busulfan–fudarabine‑ or treosulfan–fudarabine‑based myeloablative conditioning for children with thalassemia major

Lüftinger, Roswitha; Zubarovskaya, Natalia; Galimard, Jacques‑Emmanuel; Cseh, Annamaria; Salzer, Elisabeth; Locatelli, Franco; Algeri, Mattia; Yeşilipek, Akif; Fuente, Josu de la; Isgro, Antonella; Alseraihy, Amal; Angelucci, Emanuele; Smiers, Frans J.; Nasa, Giorgia La La; Zecca, Marco; Fışgın, Tunç; Ünal, Emel; Kleinschmidt, Katharina; Peters, Christina; Lankester, Arjan; Çorbacıoğlu, Selim (Annals of Hematology, 2021)

Signifcant advances in supportive care for patients with transfusion-dependent thalassemia major (TDT) have improved patients’ life expectancy. However, transfusion-associated iron overload remains a signifcant barrier ...

Search

Filters

Comparison of hematopoietic stem cell transplantation results in patients with beta-thalassemia major from three different graft types

Busulfan–fudarabine‑ or treosulfan–fudarabine‑based myeloablative conditioning for children with thalassemia major